Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2016

View Archived Issues

Trial supports the use of sodium channel blocker phenytoin in acute optic neuritis

Pivotal phase III clinical trial of intravenous meloxicam begins at Recro Pharma

FDA accepts BLA for bezlotoxumab

Supinoxin demonstrates preclinical efficacy to treat renal cancer

Replikins selects peptide Zika virus vaccine for preclinical efficacy studies

Sumitomo Dainippon Pharma updates progress of third quarter of fiscal 2015

Blend Therapeutics secures Series C financing and changes name

Urine-exosome signature validated in prostate cancer patients

Roche Diagnostics and Lilly to develop Alzheimer's diagnostic

Stemedica completes enrollment in phase I/IIa study in stroke

MSI Methylation Sciences reports results from phase II trial of MSI-195 in MDD

Alpharmagen discloses nicotinic acetylcholine alpha7 modulators

University of Texas System patents mitochondrial GLS inhibitors

Serendex starts phase II trial of inhaled molgramostim in ARDS

BIND Therapeutics gives update on BIND-014 trials

ImmunoCellular Therapeutics enters research agreement with the University of Maryland

Aprecia Pharmaceuticals obtains financing to advance 3D-printed drug pipeline

Clovis begins phase Ib/II study of atezolizumab and rociletinib

Cyramza approved in Europe for NSCLC and colorectal cancer

First patient dosed in Zimura phase II/III trial

Breakthrough therapy designation for venetoclax for AML

Incyte to stop substudy within ruxolitinib phase II colorectal cancer study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...